These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25921087)

  • 1. Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid.
    Camacho KM; Kumar S; Menegatti S; Vogus DR; Anselmo AC; Mitragotri S
    J Control Release; 2015 Jul; 210():198-207. PubMed ID: 25921087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-molecular-weight polymer-drug conjugates for synergistic anticancer activity of camptothecin and doxorubicin combinations.
    Camacho KM; Menegatti S; Mitragotri S
    Nanomedicine (Lond); 2016 May; 11(9):1139-51. PubMed ID: 27079141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer.
    Vogus DR; Evans MA; Pusuluri A; Barajas A; Zhang M; Krishnan V; Nowak M; Menegatti S; Helgeson ME; Squires TM; Mitragotri S
    J Control Release; 2017 Dec; 267():191-202. PubMed ID: 28823957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo.
    Eder JP; Chan V; Wong J; Wong YW; Ara G; Northey D; Rizvi N; Teicher BA
    Cancer Chemother Pharmacol; 1998; 42(4):327-35. PubMed ID: 9744779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation.
    Han X; Li Z; Sun J; Luo C; Li L; Liu Y; Du Y; Qiu S; Ai X; Wu C; Lian H; He Z
    J Control Release; 2015 Jan; 197():29-40. PubMed ID: 25449802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent.
    Liu J; Chi D; Pan S; Zhao L; Wang X; Wang D; Wang Y
    Int J Pharm; 2019 Feb; 557():264-272. PubMed ID: 30599233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyaluronic acid functional amphipathic and redox-responsive polymer particles for the co-delivery of doxorubicin and cyclopamine to eradicate breast cancer cells and cancer stem cells.
    Hu K; Zhou H; Liu Y; Liu Z; Liu J; Tang J; Li J; Zhang J; Sheng W; Zhao Y; Wu Y; Chen C
    Nanoscale; 2015 May; 7(18):8607-18. PubMed ID: 25898852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Camptothecin nanocolloids based on N,N,N-trimethyl chitosan: efficient suppression of growth of multiple myeloma in a murine model.
    Li Z; Li X; Cao Z; Xu Y; Lin H; Zhao Y; Wei Y; Qian Z
    Oncol Rep; 2012 Apr; 27(4):1035-40. PubMed ID: 22245938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combination cancer chemotherapy using a DNA topoisomerase inhibitor CPT-11, as a core agent--the in vitro evaluation].
    Oguro M; Seki Y
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1556-61. PubMed ID: 1651682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and optimization of a bifunctional hyaluronan-based camptothecin prodrug.
    Xu Z; Zheng W; Yin Z
    Arch Pharm (Weinheim); 2014 Apr; 347(4):240-6. PubMed ID: 24402828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic antitumor effects of liposomal honokiol combined with adriamycin in breast cancer models.
    Hou W; Chen L; Yang G; Zhou H; Jiang Q; Zhong Z; Hu J; Chen X; Wang X; Yuan Y; Tang M; Wen J; Wei Y
    Phytother Res; 2008 Aug; 22(8):1125-32. PubMed ID: 18570244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic antitumor efficacy of hybrid micelles with mitochondrial targeting and stimuli-responsive drug release behavior.
    Chen Z; Zhang Z; Chen M; Xie S; Wang T; Li X
    J Mater Chem B; 2019 Mar; 7(9):1415-1426. PubMed ID: 32255012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating Tumors at Low Drug Doses Using an Aptamer-Peptide Synergistic Drug Conjugate.
    Pusuluri A; Krishnan V; Lensch V; Sarode A; Bunyan E; Vogus DR; Menegatti S; Soh HT; Mitragotri S
    Angew Chem Int Ed Engl; 2019 Jan; 58(5):1437-1441. PubMed ID: 30537284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The self-assembling camptothecin-tocopherol prodrug: An effective approach for formulating camptothecin.
    Lu J; Liu C; Wang P; Ghazwani M; Xu J; Huang Y; Ma X; Zhang P; Li S
    Biomaterials; 2015 Sep; 62():176-87. PubMed ID: 26057133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activities and pharmacokinetics of silatecans DB-67 and DB-91.
    Yeh TK; Li CM; Chen CP; Chuu JJ; Huang CL; Wang HS; Shen CC; Lee TY; Chang CY; Chang CM; Chao YS; Lin CT; Chang JY; Chen CT
    Pharmacol Res; 2010 Feb; 61(2):108-15. PubMed ID: 19643180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoencapsulation of ABT-737 and camptothecin enhances their clinical potential through synergistic antitumor effects and reduction of systemic toxicity.
    Schmid D; Jarvis GE; Fay F; Small DM; Greene MK; Majkut J; Spence S; McLaughlin KM; McCloskey KD; Johnston PG; Kissenpfennig A; Longley DB; Scott CJ
    Cell Death Dis; 2014 Oct; 5(10):e1454. PubMed ID: 25299779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo evaluation of camptothecin nanosuspension: a novel formulation with high antitumor efficacy and low toxicity.
    Yao L; Zhao X; Li Q; Zu Y; Fu Y; Zu B; Meng X; Liu C
    Int J Pharm; 2012 Feb; 423(2):586-8. PubMed ID: 22193057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
    Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts.
    Krauze MT; Noble CO; Kawaguchi T; Drummond D; Kirpotin DB; Yamashita Y; Kullberg E; Forsayeth J; Park JW; Bankiewicz KS
    Neuro Oncol; 2007 Oct; 9(4):393-403. PubMed ID: 17652269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
    J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.